EI
BCRX icon

Ethic Inc’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ethic Inc’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
+12,289
New +$111K ﹤0.01% 1314
2022
Q1 		– Sell
-20,029
Closed -$277K – 749
2021
Q4 		$277K Buy
+20,029
New +$265K 0.02% 546

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ethic Inc's BCRX Position: Q2 2026 in Review

Ethic Inc opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 12,289 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #1314 among its holdings. This is a return to the name: Ethic Inc previously reported a position in BCRX as recently as Q4 2021.

Ethic Inc first reported a position in BCRX in Q4 2021 and has held it in 2 quarters since. The position peaked at $277K in Q4 2021. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Ethic Inc held 12,289 shares of BioCryst Pharmaceuticals worth $123K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Ethic Inc position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1314 holding.
  • Ethic Inc first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Ethic Inc's BioCryst Pharmaceuticals position peaked at $277K in Q4 2021.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.